Partnership


Product/Technology In

Clinical validated targets/MOA, New mAb drugs with solid IP rights and preclinical Proof of Concept.

To strengthen Genor's new mAb pipeline by leveraging mature external technology platforms of drug discovery.


Product Out

For Genor products in our pipeline (both Biosimilars and new mAbs), after we complete process development and preclinical study in China, we are actively seeking regional or global partners to undertake clinical development and commercialization in pharmemerging markets, as well as in more developed markets (North America, EU, JP, etc.)


For both Product In and Product Out, collaboration models can include: product licensing, co-development, JV and risk-sharing strategic partnerships.


Please contact our business development team if you have interest in any of these opportunities, or other creative new ideas/suggestions regarding collaboration. We look forward to building mutually beneficial partnerships with you!

Email: bd_genor@walvax.com